nuclear factor, erythroid 2 like 3 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored NFE2L3P1 profile across patient tissues and cancer cell-line models. NFE2L3P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NFE2L3P1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, NFE2L3P1 RNA expression shows 9,715 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight LIHC, COAD, and SKCM as cancer lineages where NFE2L3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFE2L3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFE2L3P1 survival associations across molecular data types. NFE2L3P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFE2L3P1 RNA expression–survival associations across cancer types. High NFE2L3P1 expression shows unfavorable associations in LIHC, UVM, PCPG and KIRC, but favorable associations in UCS and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NFE2L3P1 RNA expression.
This table summarizes NFE2L3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NFE2L3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFE2L3P1 shows higher tumor expression in COAD, STAD, READ, KIRC, LUAD and LUSC. The COAD box plot shows higher NFE2L3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p < 0.001).
This table shows molecular features associated with NFE2L3P1 in patient tissues and cancer cell lines. In patient samples, NFE2L3P1 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
